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Abstract. 
 
In the presence of bound Mn
 
2
 
1
 
, the three-
dimensional structure of the ligand-binding A-domain 
from the integrin CR3 (CD11b/CD18) is shown to exist 
in the ÒopenÓ conformation previously described only 
for a crystalline Mg
 
2
 
1
 
 complex. The open conformation 
is distinguished from the ÒclosedÓ form by the solvent 
exposure of F302, a direct T209ÐMn
 
2
 
1
 
 bond, and the 
presence of a glutamate side chain in the MIDAS site. 
Approximately 10% of wild-type CD11b A-domain is 
present in an ÒactiveÓ state (binds to activation-depen-
dent ligands, e.g., iC3b and the mAb 7E3). In the iso-
lated domain and in the holoreceptor, the percentage of 
the active form can be quantitatively increased or abol-
ished in F302W and T209A mutants, respectively. The 
iC3b-binding site is located on the MIDAS face and in-
cludes conformationally sensitive residues that undergo 
significant shifts in the open versus closed structures. 
We suggest that stabilization of the open structure is in-
dependent of the nature of the metal ligand and that 
the open conformation may represent the physiologi-
cally active form.
Key words: integrin activation ¥ A-domain ¥ crystal 
structure ¥ complement iC3b ¥ G proteins
 
T
 
he
 
 interaction of integrins with their ligands is an
essential step in regulating many cellular functions
(reviewed in Hynes, 1992). Integrin binding to vari-
ous ligands is divalent cation dependent, and is tightly reg-
ulated by inside-out and outside-in signaling events. The
mechanisms through which these signals modulate inte-
grinÐligand interactions are not known. Biophysical, bio-
chemical, and immunochemical studies have revealed that
integrins exist in low and high affinity states (Du et al.,
1993). Activation signals lead to conformational changes
that extend to the receptorÕs extracellular ligand-binding
regions (Diamond and Springer, 1993; Landis et al., 1993;
Bilsland et al., 1994; Kamata and Takada, 1994; Randi and
Hogg, 1994; Zhou et al., 1994). It has also been proposed
that rapid oscillations between the low and high affinity
states of integrins contribute to the adhesionÐdeadhesion
cycles during cell migration and cytolysis (Dransfield et
al., 1992).
Recent studies in several integrins have identified two
major ligand-binding sites. One is located within an A-type
domain (A- or I-domain) present in the 
 
a
 
 subunits of seven
integrins (Diamond et al., 1993; Michishita et al., 1993;
Landis et al., 1994; Randi and Hogg, 1994; Zhou et al., 1994;
Tuckwell et al., 1995; Xie et al., 1995). A second region is
located in a highly conserved segment of all the integrin 
 
b
 
subunits (DÕSouza et al., 1988; Smith and Cheresh, 1988;
Andrew et al., 1994; Bajt and Loftus, 1994; DÕSouza et al.,
1994; Kamata et al., 1995
 
a
 
). Secondary structure, hydropa-
thy, and protein threading algorithm predict that this seg-
ment also adopts an A-type fold (Lee et al., 1995
 
b
 
; Ar-
naout, M.A., unpublished observations), suggesting that
structureÐfunction analysis of the A-domain is likely to
shed light on the structural basis of affinity switching in all
integrins.
The recombinant CD11b A-domain (r11bA) from the
 
b
 
2 integrin CR3 (CD11b/CD18, 
 
a
 
M
 
b
 
2) binds directly to
several ligands in a divalent cationÐdependent manner
(Michishita et al., 1993; Lee et al., 1995
 
b
 
). Some of these
ligands (e.g., iC3b, fibrinogen, CD54 [ICAM-1], and the
ligand-mimetic mAb 7E3) can only interact with the ho-
loreceptor in its active state. Others such as neutrophil in-
hibitory factor (NIF)
 
1
 
 bind to CR3 regardless of its activa-
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 MFI, mean fluorescence intensity;
MIDAS, metal ionÐdependent adhesion site; NIF, neutrophil inhibitory
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tion status (Michishita et al., 1993; Rieu et al., 1994; Ueda
et al., 1994; Zhou et al., 1994; Lee et al., 1995
 
b
 
; Xie et al.,
1995). The ability of both activation-dependent and -inde-
pendent ligands to bind to r11bA suggests that the r11bA
either becomes active when removed from the holorecep-
tor or exists in different affinity states. The crystal struc-
tures of several integrin A-domains have been published.
The structures invariably include a dinucleotide-binding
fold (similar to that of small G proteins where the fold was
first described), a buried 
 
b
 
 sheet surrounded by amphi-
pathic helices (seven in CD11b A-domain), and a solvent-
exposed metal ion located in a crevice at the COOH-ter-
minal end of the 
 
b
 
 sheet. The metal ion is coordinated by a
group of conserved amino acids forming the metal ionÐ
dependent adhesion site (MIDAS). The first published
structure of r11bA complexed to Mg
 
2
 
1
 
 (Lee et al., 1995
 
b
 
)
(ÒopenÓ form) showed significant differences from a sec-
ond ÒclosedÓ conformation of r11bA complexed to Mn
 
2
 
1
 
(Lee et al., 1995
 
a
 
; Baldwin et al., 1998) and from all
CD11a crystal structures (Qu and Leahy, 1995): in the
open form, a glutamate from a neighboring molecule
provides the sixth metal coordination site. In addition, two
phenylalanines (F275 and F302) are solvent exposed due
to conformational changes that involve several loops.
Based on mechanistic similarities with the ÒactiveÓ and
ÒinactiveÓ structures of the signaling proteins ras and G
 
a
 
,
we suggested that this open form is active while the closed
conformation is inactive (Lee et al., 1995
 
a
 
). Because the
open and closed states of r11bA formed in the presence of
different metal ions (Mg
 
2
 
1
 
 and Mn
 
2
 
1
 
, respectively) and
because of the uniformly activating effect of Mn
 
2
 
1
 
 on inte-
grins, a counterargument was made that the Mn
 
2
 
1
 
-com-
plexed form represents the active species (Qu and Leahy,
1995). More recently, it was argued based on theoretical
considerations that the open form is a structural artifact
that arises secondary to a truncated COOH terminus
(Baldwin et al., 1998).
In this communication, we demonstrate that r11bA crys-
tallized in the presence of Mn
 
2
 
1
 
 can also assume the open
conformation, indicating that generation of this structure
is independent of the nature of the metal ion. The func-
tional relevance of the structural changes observed be-
tween the open and the closed conformations (changes in
MIDAS topology, solvent exposure of F302 and F275, and
coordination of the metal ion to T209) was probed
through mapping of the iC3b-binding site and by muta-
tional analysis of certain conformationally sensitive resi-
dues. The binding site in CR3 for iC3b incorporates con-
formationally sensitive residues that move up to 3.5  in
the two structures (relative to the bound manganese metal
ion). F302W and F275R substitutions that introduce bulky
or charged residues at these two positions, respectively,
increased r11bA (and holoreceptor) binding to activation-
dependent ligands. On the other hand, a T209A substitu-
tion, intended to abolish the direct T209Ðmetal coordina-
tion found in the open form, resulted in a complete loss of
r11bA (and holoreceptor) binding to activation-depen-
dent ligands. However, none of these mutants affected the
interaction of r11bA or the holoreceptor with the activa-
tion-independent ligand NIF. Analysis of the interaction
of wild-type (WT) r11bA with iC3b using surface plasmon
resonance identified active and inactive populations of the
A-domain, with the latter predominating. The proportion
of the active form increased by 2.5-fold in the F302W do-
main compared with WT and disappeared by the T209A
substitution. We suggest that the active and inactive states
may correspond to the open and closed crystal structures,
respectively.
 
Materials and Methods
 
Reagents and Antibodies
 
Restriction and modification enzymes were purchased from New England
Biolabs Inc. (Beverly, MA), Boehringer Mannheim (Mannheim, Ger-
many), or GIBCO BRL (Gaithersburg, MD). The anti-CD11b mAbs
OKM10, 44, 903, 904, 7E3, and the anti-CD18 mAb TS1/18 have been de-
scribed previously (Arnaout et al., 1983; Coller, 1985; Dana et al., 1986;
Wright et al., 1987). Purified fibrinogen was a kind gift from Dr. Jari
Ylanne (University of Helsinki, Helsinki, Finland). mAb 7E3 and FITC-
conjugated 7E3 were gifts from Dr. Barry S. Coller (Mount Sinai Medical
Center, New York).
 
Site-directed Mutagenesis
 
This was carried out in pcDNA3 or 
 
p
 
H3M expression vectors as described
(Kunkel et al., 1987; Deng and Nicoloff, 1992). Some of the primers used
have been published elsewhere (Rieu et al., 1996). The following addi-
tional mutagenic primers were used, each followed by the introduced
unique restriction site: F302R reverse, CTGAATGGTCTTAAGAGC-
CTCTCTGTTATTCACCTG (AflII); F302W forward, CGTGTTCCAG-
GTGAATAACTGGGAAGCTTTGAAGACCATTCAGAACC (Hind-
III); F302Y reverse, CTGAATGGTCTTAAGAGCCTCGTAGTTATT-
CACCTG (AflII); F275R reverse, TTGGCGGGATTTCTCGGACC-
GTCTGGCATCTCCCACCCC (RsrII); T209A forward, CTGCTTGG-
GCGAGCTCACACGGCCACG (SacI); G247A forward, CGGATGG-
AGAAAAGTTTGCGGATCCCTTGGGATATGA (BamHI); and P249A
forward, GGAGAAAAGTTTGGCGATGCCTTGGGATATGAGGA-
CGTCATCCCT (AatII). Each mutation was confirmed by the presence
of the introduced restriction site and by direct DNA sequencing (Sanger
et al., 1977). The recombinant DNA work used standard protocols (Mani-
atis et al., 1989).
 
Protein Purification and Characterization
 
Recombinant WT r11bA and its mutants F302W, T209A, and D140GS/
AGA were expressed as GST fusion proteins in 
 
Escherichia coli
 
, as de-
scribed elsewhere (Michishita et al., 1993; Ueda et al., 1994). cDNA se-
quencing of the 3
 
9
 
 end of the WT and mutant r11bA constructs predicts a
protein that terminates with A318 of CD11b plus the vector sequence
GNSS. The fusion proteins were purified by affinity chromatography on
glutathione-coupled beads, and cleaved with thrombin to release the re-
combinant A-domains. WT and mutant r11bA were further purified by
ion exchange chromatography on a Mono S HR5/5 column using the
FPLC system (both from Pharmacia, Piscataway, NJ). Analysis of the pu-
rified proteins on 12% SDS-PAGE revealed a single band of the expected
size after staining with Coomassie blue (data not shown).
The purified thrombin-cleaved WT r11bA was digested overnight with
immobilized TPCK-trypsin (Pierce, Rockford, IL) as described (Lee et al.,
1995
 
b
 
), and then repurified by gel filtration on a Superdex-75 column. The
NH
 
2
 
 terminus of the trypsin-treated r11bA begins with G127, as deter-
mined by protein sequencing. The COOH termini of both thrombin- and
trypsin-treated preparations were sequenced using the Mayo Protein Core
Facility and were found to be identical. Both proteins end with A318 of
the native domain followed by the vector-derived sequences GD (instead
of the predicted N), with the two COOH-terminal serines detected in
lower quantities (data not shown).
The thrombin- and trypsin-treated preparations were also analyzed by
LC-MS using MassLynx software. The measured mass of the thrombin-
cleaved protein is 24,235.8 (calculated mass using monoisotopic masses
based on the predicted 212Ðamino acid peptide is 24,143.5; 
 
measured
 
 
 
2
 
calculated mass
 
 [
 
D
 
]
 
 5 
 
92.3; expected measured error of 
 
1
 
0.02%). The
measured mass of the limited trypsin-cleavage product (beginning with
G127 and ending with GNSS) is 22,383.7 (calculated 22,293.6, 
 
D 5 
 
90.1).
LC-MS analysis of the tryptic sequence fragments resulting from an ex- 
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haustive digest of the thrombin-cleaved A-domain allowed an assignment
of all of the sequence up to R313. By difference, the mass of the COOH-
terminal sequence (E314KIFAGNSS) must be 1025.7 (calculated 952.2, 
 
D 5
 
73.5), suggesting that a modification in the COOH-terminal sequence
(most likely in the vector sequence) is responsible for the larger measured
mass of the domain.
 
Crystallization
 
The trypsin-treated r11bA was desalted on a Bio-Gel P-6DG column
(BIO-RAD, Richmond, CA) and concentrated to 16 mg/ml for crystalliza-
tion using a centricon unit with a 10 K molecular mass cutoff (Amicon
Inc., Beverly, MA). Crystals were grown using the hanging drop vapor dif-
fusion method by mixing equal volumes (5 
 
m
 
l) of protein and reservoir so-
lution (23% polyethylene glycol 8 K, 0.05 M Tris, pH 8.8, 100 mM MnCl
 
2
 
),
at room temperature (modified from Lee et al., 1995
 
b
 
). Crystals started to
form within a week, grew to a typical size of 0.3 mm 
 
3
 
 0.05 mm 
 
3
 
 0.04 mm
in 3Ð4 wk, and belonged to the tetragonal space group P4
 
3
 
 (Table I).
These crystals are isomorphous with the Mg
 
2
 
1
 
-containing crystals (Lee
et al., 1995
 
b
 
).
 
Data Collection and Structure Determination
 
A single crystal was used to collect a 2.7 resolution data set, at 100 K, on
beamline X25 of the National Synchrotron Light Source at the Brook-
haven National Laboratory using a MarResearch imaging plate detector.
Data were processed with DENZO and SCALEPACK (Otwinowski,
1991) to an R
 
sym
 
 of 12.2%. The starting model was the refined 1.8  Mg
 
2
 
1
 
structure (pdb accession code lido) (Lee et al., 1995
 
b
 
) comprising residues
D132 to K315, with the metal and water molecules removed. The struc-
ture was refined using the computer program PROFFT (Finzel, 1987) to a
final R factor of 19.8% (1.5 sigma cutoff). The final model comprises all
nonhydrogen atoms of residues D132 to K315, 25 water molecules, and
one manganese metal ion. Water molecules were placed and maintained
based on suitable peaks in difference maps, reasonable hydrogen bond ar-
rangements, and refined temperature factors of 
 
,
 
35. Five protein residues
have energetically unfavorable phi-psi angles as demonstrated by a Ram-
achandran plot (Gln163, Thr169, Ser177, Phe184, and Leu206), and in-
clude one of the residues also noted in the 1.8 structure (Ser177). Exam-
ination of hydrogen bonding patterns and local interactions suggest
plausible explanations for the unusual geometry of four of the five resi-
dues.
 
COS Cell Transfections
 
COS M7 simian fibroblastoid cells at 60Ð70% confluence were transfected
with supercoiled cDNAs encoding WT and mutant CD11b and CD18 as
described (Michishita et al., 1993). Transfected COS cells were grown for
24 h in IscoveÕs modified DulbeccoÕs medium (BioWhittaker, Inc., Walk-
ersville, MD) supplemented with 10% FBS, 2 mM glutamine, 50 IU/ml
penicillin and streptomycin at 37
 
8
 
C. Cells were then washed, detached
with 0.1% trypsin-EDTA, and seeded in replicates for 24 h onto 24- or 48-
well plates (Costar Corp., Cambridge, MA) or 100-mm petri dishes. Con-
fluent monolayers in 24- or 48-well plates were then used for cell-surface
antigen quantification and ligand-binding studies and those on petri dishes
for immunoprecipitation studies.
 
Heterodimer Formation
 
This was assessed as described previously (Michishita et al., 1993). Conflu-
ent monolayers of transfected COS cells from 100-mm petri dishes were
washed in PBS containing 5 mM EDTA, and each plate was solubilized in
0.5 ml of PBS containing 1% Triton X-100, 2 mM PMSF, 2 mg/ml leupep-
tin, and 2 mg/ml pepstatin A (Sigma Chemical Co., St. Louis, MO). The
detergent-soluble fraction was harvested after centrifugation and immu-
noprecipitated using the anti-CD18 mAb TS1/18. Washed immunopre-
cipitates were separated by SDS-PAGE under reducing conditions
(Laemmli, 1970) and electroblotted onto Immobilon-P membranes (Milli-
pore Corp., Bedford, MA). After blocking with 10% nonfat milk in PBS,
the membrane was incubated for 1 h with the anti-CD11b mAb 44 (Ar-
naout et al., 1983). Detection of proteins was performed using the en-
hanced chemiluminescence kit from Amersham Corp. (Buckingham-
shire, UK).
 
Generation of CHO Cell Lines Expressing WT and 
Mutant CR3
 
The CHO-K1 cell line was maintained in HamÕs F12 nutrient mixture
(GIBCO BRL) supplemented with 10% FBS, 100 U/ml penicillin, and 100
 
m
 
g/ml streptomycin. Transfection of CHO-K1 cells with WT or F302W
CD11b and CD18 cDNA, in pcDNA3/Neo and 
 
p
 
H3M plasmids, respec-
tively, was performed using the calcium phosphate
 
 
 
precipitation method
as described previously (Golenbock et al., 1993). After 48 h, the medium
was replaced with fresh medium containing 1 mg/ml of G418. The G418-
resistant cell population was analyzed for CR3 expression with a FACS-
can
 
¨
 
 flow cytometer (Becton Dickinson, Mountain View, CA), and the
CD11b and CD18 double-positive cells were enriched by cell sorting. The
CHO cells expressing WT and F302W CR3 were then cloned by limiting
dilution. CHO cells transfected with pcDNA/Neo alone were made and
used as a negative control.
 
Preparation of Complement iC3b-coated Erythrocytes 
and Purification of iC3b
 
Sheep erythrocytes coated with complement iC3b were prepared as de-
scribed (Michishita et al., 1993). EiC3b (1.5 
 
3
 
 10
 
8
 
 cells/ml) were labeled
with 5-(and-6)-carboxy fluorescein (Molecular Probes, Eugene, OR)
(Ueda et al., 1994), washed, and resuspended to the original concentration
for use in the binding studies. In some experiments, EiC3b cells were sur-
face labeled with biotin by incubating the cells with 0.5 mg/ml sulfo-NHS-
biotin (Pierce) for 30 min at 4
 
8
 
C.
iC3b was purified from fresh human serum by affinity chromatography
as described (Ross et al., 1987; Cai and Wright, 1995). In brief, 50 ml hu-
man serum was treated with 20 mM iodoacetamide (Sigma) to block all
free sulfhydryl groups. After extensive dialysis, the serum was incubated
with 2Ð3 g of activated thiol-Sepharose 4B (Sigma) for 2 h at 37
 
8
 
C. The
Sepharose activates the complement cascade, and the C3 is captured by
thiol-Sepharose through its newly generated free sulfhydryl group. iC3b
was eluted with 10 mM 
 
l
 
-cysteine and further purified by ion exchange
chromatography on a Mono Q HR5/5 column using FPLC system (both
from Pharmacia). The purity of iC3b was examined on 8% SDS-PAGE.
 
mAb and Ligand Binding to WT or Mutant
CR3-transfected COS and CHO Cells
 
Binding of mAbs, biotinylated NIF, or EiC3b to COS cells was assessed si-
multaneously as described (Michishita et al., 1993; Rieu et al., 1996). In
brief, triplicate wells (from a 48-well plate) containing confluent-trans-
fected COS cells were incubated with mAbs OKM10, 903, or TS1/18 (each
at 2 
 
m
 
g/ml), or biotinylated NIF (at 400 ng/ml) in Tris-NaCl buffer, pH 7.4,
containing 1 mM MgCl
 
2
 
, 1 mM CaCl
 
2
 
, 1% BSA (TMB buffer), and 0.02%
sodium azide for 1 h at 4
 
8
 
C. Cells were then washed and incubated with
 
125
 
I-labeled goat antiÐmouse immunoglobulin (New England Nuclear,
Boston, MA) (for mAbs) or with 
 
125
 
I-coupled avidin (Amersham, Arling-
ton Heights, IL) (for NIF) under similar conditions. After washing, cells
 
Table I. Data Collection and Summary of Refinement Results
 
Space group: P4
 
3
 
Unit cell: a 
 
5
 
 b 
 
5
 
 45.15, c 
 
5
 
 95.60
Number of unique reflections 
 
5
 
 4,305
Percent completion 
 
5
 
 81.7% (0 sigma)/67.8 (2 sigma)
Average I/error 
 
5
 
 6.8
R-sym* 
 
5
 
 12.2
Resolution limits 
 
5
 
 10.0Ð2.7 
Refinement program 
 
5
 
 PROFFT
R factor 
 
5
 
 19.8 (1.5 sigma cutoff)
Protein residues 
 
5
 
 D132ÐK315
Number of water molecules 
 
5
 
 25
Number of metal (manganese) ions 
 
5
 
 1
Root mean square deviations from ideal values
 
à
 
Bond lengths: 0.008  sigma 0.030
Bond angle distances: 0.015  sigma 0.040
Planarity: 0.013  sigma 0.050
 
*Sum (Abs(I 
 
2
 
 
 
,
 
I
 
.
 
))/Sum (I).
 
à
 
Sigma values are the inverse square root of the restraint weight used during refine-
ment. The coordinates will be deposited in the protein data bank. 
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were solubilized with 1% SDS, 0.2 N NaOH and the extracts were
counted. Specific binding was obtained by subtracting the background
binding to mock-transfected COS cells (usually 
 
,
 
5% of total binding).
The binding data from three independent experiments were pooled and
expressed as histograms representing mean 
 
6
 
 SEM, before the mutants
were decoded. Binding of mAbs and NIF to COS cells was normalized for
the percentage of binding obtained with WT as follows:% 
 
binding
 
 
 
5 
 
(
 
mu-
tant binding
 
/
 
WT binding
 
) 
 
3
 
 100.
EiC3b binding was assessed by adding 40 
 
m
 
l of fluoresceinated EiC3b
in TMB buffer to triplicate confluent wells (from a 24-well plate) in a total
volume of 500 
 
m
 
l followed by a brief 15-s spin at 800 rpm/min. After a
5-min incubation at 37
 
8
 
C and two washes, the cells were solubilized with
1% SDS, 0.2 N NaOH and the fluorescence was quantified (excitatory
wavelength, 490 nm; emission wavelength, 510 nm) using a SLM 8000
fluorometer (SLM Instruments, Urbana, IL) (Michishita et al., 1993). Spe-
cific binding was obtained by subtracting background binding to mock-
transfected COS cells. Binding was normalized to the percentage of bind-
ing obtained with WT.
Purified iC3b and fibrinogen were diluted to 50 
 
m
 
g/ml and 50 
 
m
 
l of each
diluted protein was placed in triplicates at the well center of 24-well non-
tissue culture plates (Becton Dickinson). After incubating overnight at
4
 
8
 
C, the plates were washed and blocked with BSA. WT- or F302W-
expressing CHO cells (10
 
6
 
 in 400 
 
m
 
l of TMB buffer) were added to each
well and incubated for 30 min at 37
 
8
 
C. After three washes, bound cells
were quantified by detecting the cellular acid phosphatase level. Binding
to Neo-transfected CHO cells was subtracted. Binding was normalized to
the percentage of binding obtained with WT.
 
Flow Cytometry
 
WT-, F302W-, or Neo-transfected CHO cells were washed and resus-
pended in HamÕs F12 nutrient mixture containing 2 mM MnCl
 
2
 
 and 0.5%
BSA to 6 
 
3
 
 10
 
6
 
/ml. To a 50-
 
m
 
l cell suspension, FITC-conjugated mAbs
7E3, 44 (Sigma), or mouse IgG1 (Sigma) were added to a final concentra-
tion of 20 
 
m
 
g/ml, and incubated for 20 min at room temperature. The cells
were washed, pelleted, resuspended in PBS containing 1% formaldehyde,
and then analyzed immediately on a Becton Dickinson FACScan
 
¨
 
 flow
cytometer. The fraction of CR3 recognized by 7E3 (high affinity CR3) was
expressed as a ratio of the mean fluorescence intensity (MFI) generated
by 7E3 to that generated by mAb 44 (which recognizes the whole popula-
tion of expressed CR3) as follows: 
 
high affinity CR3
 
 (%) 5 (MFI of 7E3)/
(MFI of 44) 3 100.
mAb and Ligand Binding to Purified WT and
Mutant r11bA
This was carried out on three different WT and F302W r11bA prepara-
tions as described (Ueda et al., 1994) with the following modifications. 50
ml of PBS, pH 7.4, containing 2 mg of WT or mutant r11bA was placed in
triplicates in 96-well plates overnight at 48C. Wells were washed, blocked
with BSA, and then used in mAb or ligand-binding assays. Reactivity of
r11bA with the anti-CD11b mAbs 44, 904, and 7E3 was assessed by incu-
bating r11bA-containing wells with each mAb (10 mg/ml) for 1 h at room
temperature, followed by a washing step, and a second incubation with al-
kaline phosphataseÐcoupled secondary antibody (Sigma) for an additional
hour. Color reaction was then developed by adding 1 mg/ml p-nitrophe-
nyl-phosphate, and quantified using a plate reader.
Binding of biotinylated EiC3b to immobilized WT or mutant r11bA
was carried out by incubating 3 3 106 EiC3b cells in 50 ml veronal buffered
saline, pH 7.4, containing 1 mM MgCl2, 1 mM CaCl2, and 0.1% gelatin, for
15 min at 378C. After gentle washing, bound EiC3b were fixed with 1%
glutaraldehyde, blocked with BSA, and treated with streptavidinÐalkaline
phosphatase conjugate and p-nitrophenyl-phosphate. Bound EiC3b was
quantified by measuring the absorbance at 405 nm. Binding of biotiny-
lated NIF to immobilized WT and mutant r11bA was carried out as de-
scribed (Rieu et al., 1994). Background binding (binding to metal-defec-
tive mutant D140GS/AGA) was subtracted.
BIAcoreª Analysis
The apparent equilibrium constants for binding of three different prepara-
tions of WT and F302W r11bA to the complement fragment iC3b were
measured using surface plasmon resonance on a BIAcoreª (BIAcore
AB, Uppsala, Sweden). The Biosensor device was used in accordance
with the manufacturerÕs instructions. In brief, iC3b was covalently coupled
via primary amine groups to the dextran matrix of a CM5 sensor chip
(BIAcore AB). BSA immobilized in the same way was used as a control
surface. The WT and F302W A-domain proteins were flowed over the
chip at 5 ml/min. TBS (20 mM Tris-HCl, pH 8.0, 150 mM NaCl) with 2 mM
MgCl2 and 0.005% P20 (BIAcore AB)  was used as running buffer
throughout. 1 M NaCl in 20 mM Tris-HCl, pH 8.0, was used to remove the
bound proteins and to regenerate the surface for further binding experi-
ments. The binding was measured as a function of time. The binding data
(after subtracting background binding to BSA-coated chip) were analyzed
using Scatchard plots as described (DallÕAcqua et al., 1996). For quantita-
tively determining the active proportion of the A-domain proteins, iC3b
(an activation-dependent ligand) and mAb 904 (an activation- and metal-
independent ligand) were each immobilized on a CM5 sensor chip. The
WT and F302W A-domain proteins were flowed over the chip at 2 ml/min.
The initial binding rates (obtained from linear regression of binding data
over a 10Ð15-s period from the initial binding phase) under conditions of
mass transfer limitation are proportional to the active protein concentra-
tion and independent of receptor-ligand affinity (Karlsson et al., 1993).
Two different amounts of ligand (6,300 and 8,000 RU for iC3b; 4,200 and
6,200 RU for 904) were first used to examine the mass transfer limiting
conditions. 100 mM HCl was used to regenerate the mAb 904 surface. The
higher ligand densities of iC3b and 904 were used to determine the active
proportion of the A-domain proteins.
Results and Discussion
Crystal Structure of the CD11b A-Domain in Complex 
with Mn21
The structure of r11bA crystallized in the presence of
Mn21 is nearly identical to that of the Mg21 form (Lee et al.,
1995b). The bound manganese ion is located in a shallow
crevice at the top of the internal b sheet where it is coordi-
nated by S142, S144, T209, and two water molecules. The
sixth Mn21 coordination site is provided by the side chain
of E314 from a neighboring A-domain within the crystal
lattice (Fig. 1 A). These structures are referred to as
adopting the open conformation since F275 and F302
are solvent exposed (Fig. 1 C). The closed conformation
(burial of F302, F275, or their equivalents into the hy-
drophobic core of the protein, a break in the T209 [or
equivalent threonine]Ðmetal bond; Fig. 1, B and D) and a
corresponding change in surface charge and topology of
MIDAS (Lee et al., 1995a,b; Qu and Leahy, 1995; Qu and
Leahy, 1996; Emsley et al., 1997; Baldwin et al., 1998) are
found in all remaining integrin A-domain structures deter-
mined to date. This includes the Mn21 and no-metal forms
of CD11bA, Mn21 and Mg21 forms of CD11aA, and a
Mg21-complexed form of CD49bA. Taken together, these
findings suggest that the integrin A-domain exists prima-
rily in two conformations, the formation of which is unaf-
fected by the nature of the metal ion in the active site or
the experimental conditions of protein purification and
crystal growth.
Mapping of the Binding Site for
the Activation-dependent Ligand iC3b
We introduced single or double amino acid substitutions
in residues scattered in all 11 loops and adjacent helices of
the r11bA structure with the exception of the largely
hydrophobic bC-a2 loop (H183FT) and the a2-a3 loop
(N192PNP) (where a P195A substitution had detrimental
effects on metal ion coordination; Michishita et al., 1993).
All of the targeted residues had solvent-exposed side
chains (relative total side chain accessibility values ranged
from z25 to 100%), and were replaced either with resi-Li et al. Affinity Modulation in Integrins 1527
dues from CD11a (which does not bind to iC3b or NIF),
with residues having the opposite charge, or with alanines.
The WT and mutant receptors expressed in COS cells
were then probed with mAbs or ligands as described
(Michishita et al., 1993; Rieu et al., 1996). None of the mu-
tations affected the normal expression of the receptors as
judged by binding of the anti-CD11b mAbs OKM10 (Fig.
2 A), 903, and the anti-CD18 mAb TS1/18 (Rieu et al.,
1996; and data not shown). Binding of G143M, D149K,
E178E/AA, T203Q/KH, R208L, F246K, and E278K/AA
receptors to iC3b was either absent or significantly re-
duced (Fig. 2 B), whereas that of E244K and D273K was
significantly increased. Gain-of-function mutations are not
unusual in contact regions of proteinÐprotein complexes
(Clackson and Wells, 1995). A smaller but still significant
increase in binding of K166S/AA was also observed. None
of the remaining eight mutations (involving 11 amino ac-
ids) affected iC3b binding significantly. The loss of iC3b
binding to some mutants was not caused by defective for-
mation of the heterodimer (Fig. 2 B,  inset; Rieu et al.,
1996) or an inability of the domain to bind metal: Mn54
bound directly to G143M, D149K, E178E/AA, and R208L
r11bA mutants, and the metal-dependent interaction of bi-
otinylated NIF with the remaining mutants T203Q/KH,
E244K, F246K, D273K, and E278K/AA was normal (Rieu
et al., 1996). With the exception of E278K and T203 (PQ
and K, respectively, in mouse), the residues involved in
iC3b binding were either identical (G143, D149, E179,
Q204, R208, E244, and F246) or conserved (E178 and
D273) in mouse CR3 (Pytela, 1988). This may explain the
ability of mouse and human CR3 to bind to human and
mouse iC3b, respectively. The relative affinity of these
cross-species interactions has not been determined.
Previous studies have examined the structural basis of
CR3 binding to iC3b. One study focused on residues in the
bD-a5 loop (F246-Y252) adjacent to D242 (McGuire and
Bajt, 1995), since these residues are absent in the nonÐ
iC3b-binding CD11a A-domain (Rieu et al., 1996), and
peptides spanning this loop or immediately preceding it af-
fect iC3b binding (Ueda et al., 1994). Deletion of the bD-
a5 loop in human CR3 or a D248A substitution abolished
receptor binding to iC3b (McGuire and Bajt, 1995). The
bD-a5 loop was among those targeted in our mapping
study, and replacement of one of its residues F246 with
lysine (F246K) abolished iC3b binding, whereas G247A
and P249A substitutions had no effect (Fig. 2 B). An
F246A substitution also reduced iC3b binding, although
less dramatically than the F246K substitution (McGuire
and Bajt, 1995). We have not included D248 and Y252 in
our mutagenic approach since the respective side chains
are not solvent-exposed (relative total side chain accessi-
bility values were 0 and z10%, respectively, in either
conformation). Detrimental structural effects might have
caused the defective binding of these mutants to iC3b.
Figure 1. The Mn21 structure
of r11bA. A and B show a
close-up of the MIDAS motif
in the open (this report) and
closed (Lee et al., 1995a) con-
formations, respectively. The
Mn21 metal ion in both forms
is displayed in gray, oxygen
atoms and water molecules
are in red, and the protein
backbone is shown schemati-
cally as a light green ribbon.
C and D show a top view of
r11bA structure (ribbon back-
bone) with the major changes
in the open (C) (this report)
and closed (D) Mn21-com-
plexed conformations. The sol-
vent-exposed Mn21 is shown
(light green ball) surrounded
by the largely buried metal
coordinating residues D140,
S142, S144, T209, and D242
(side chains are outlined in
yellow and red). F302 and
F275 are shown in light blue.
The figure was built using
QUANTA (Molecular Simu-
lations Inc., Mountain View,
CA). See the text for details.The Journal of Cell Biology, Volume 143, 1998 1528
Supportive evidence is provided by the finding that dele-
tion of D248-Y252 led to the loss of CR3 binding to three
different metal-dependent ligands including NIF (Zhang
and Plow, 1996b). The present data reveal that residues
from five different loops and two of their connecting heli-
ces contribute to the iC3b-binding site in r11bA.
The iC3b-binding Site Is Located on the MIDAS Face 
and Involves Conformationally Sensitive Residues
The residues involved in iC3b binding mapped to the MI-
DAS face of r11bA, in close proximity to the metal ion
(Fig. 3). Two other ligands, NIF and CD54, also require
residues expressed on the MIDAS face for interaction
with CD11b and CD11a receptors, respectively (Rieu et al.,
1994; Huang and Springer, 1995). The divalent cationÐ
dependent interaction of iC3b with CR3 or its isolated
r11bA requires key glutamate residues in iC3b (Tanigu-
chi-Sidle and Isenman, 1994). The ring-like arrangement
of the iC3b-binding site around the metal ion lends sup-
port to our hypothesis that the exogenous metal-coordi-
nating glutamate in the open structure may be a mimic
Figure 2. Effects of A-domain
mutants on CR3 surface ex-
pression and iC3b binding.
(A) Histograms (mean 6
SEM, n 5 3) showing the rel-
ative binding of anti-CD11b
mAb OKM10 to COS cells
expressing mutant CR3. (B)
Histograms (mean 6 SEM,
n 5 3) showing the relative
binding of iC3b to COS cells
expressing CR3 mutants. (In-
set) Radioautograph of a
Western blot showing com-
parable amounts of the
CD11b subunit in anti-CD18
immunoprecipitates from
COS cells expressing WT or
mutant CR3. No CD11b was
seen in anti-CD18 immuno-
precipitates from COS cells
transfected with CD18
cDNA alone.
Figure 3. Protein move-
ments of the iC3b-binding
site in the two structures. Po-
sition of the side chains of
residues involved in iC3b
binding on MIDAS relative
to Mn (white ball) in the open
(red) and closed (yellow)
structures. The residues that
are also involved in NIF
binding, G143, D149, E178E,
and R208 (based on single or
double amino acid substitu-
tions) (Rieu et al., 1996), un-
dergo little movement in the
two structures (see also Ta-
ble II).Li et al. Affinity Modulation in Integrins 1529
of an integrin interaction with ligand (Lee et al., 1995b).
Recent docking of collagen and CD54 ligands on the
A-domains of CD49b and CD11a, respectively, showed
that the respective glutamates can be accommodated in
the A-domain without severe steric clashes, suggesting
that the metal ion in the A-domain can coordinate the
glutamate ÒligandsÓ directly (Emsley et al., 1997; Bella et
al., 1998). Co-crystals of the A-domain in complex with ac-
tivation-dependent and -independent ligands will be re-
quired to determine if the metal ion contributes directly to
ligand coordination.
The residues G143, D149, R208, and E178E that are
shared by the binding sites for iC3b and NIF (an activa-
tion-independent ligand) are located on one side of the
metal ion (Fig. 3). Interestingly, the relative position of
these residues in relation to the metal ion changed little
(the Ca-metal ion distances generally #1 ) in the open
and closed conformations (Table II). In contrast, the rela-
tive position of most of the residues which selectively af-
fect iC3b binding changed significantly in the two confor-
mations with respect to the metal ion (Ca-metal ion
distances changed by several angstroms in some cases)
(Table II). Thus, a major distinguishing feature between
the open and closed conformations, namely the change in
topology on the MIDAS face, may be relevant to the acti-
vation-dependent binding of CR3 to iC3b. Conforma-
tional changes on the MIDAS face may be required to de-
velop an optimal binding interface between CR3 and its
physiologic ligands.
Effects of F302W or F275R Substitutions on Receptor 
Binding to iC3b, NIF, and mAb 7E3
A second structural difference between the open and
closed r11bA conformations is a major increase in the sol-
vent accessibility of the conserved F302 and F275 in the
open conformation (relative total side chain accessibility
values increase from 6.4 to 81.5% for F302 and from 0.3
and 26.4% for F275). Therefore, we assessed the effects of
introducing bulky or charged side chains at these positions
on the activation-dependent interaction of CR3 with iC3b.
F302 was replaced with arginine, tryptophan, or tyrosine
(as a control), and F275 was replaced with arginine. The
CR3 mutant F302R was not expressed on the cell surface
(data not shown). The remaining mutants were surface ex-
pressed in normal quantities relative to the WT receptor
(Fig. 4 A). To determine the functional profile of the re-
sulting mutants, the recombinant receptors were probed
with the activation-dependent and -independent ligands
iC3b and NIF, respectively. Whereas the binding of iC3b
to the conserved F302Y receptor was indistinguishable
from that of WT, iC3b binding to F302W and F275R was
significantly increased (Fig. 4 B). On the other hand, NIF
bound equally to F302Y, F302W, and F275R receptors.
Similar observations were obtained in stable CHO cell
lines expressing comparable amounts of WT or F302W
(Fig. 4 C). Increased binding of F302W was not limited to
iC3b, but also occurred with fibrinogen, another activa-
tion-dependent ligand (Fig. 4 C).
The 11bA recognizing mAb 7E3 (Zhou et al., 1994) is a
ligand-mimetic antibody whose binding to the holorecep-
tor in leukocytes or in cells transfected with recombinant
CR3 is stimulated by the same agonists that trigger physio-
logic ligand binding (Altieri and Edgington, 1988; Altieri,
1991; Simon et al., 1997). 7E3 is thus very useful in detect-
ing high affinity CR3 in intact cells. The estimate of the
later species is z10% when 7E3 or a second ligand mi-
metic mAb CBRM1/5 (Diamond and Springer, 1993; Si-
mon et al., 1997) is used. To assess the impact of the
F302W modification on affinity modulation in CR3, we
compared the binding of 7E3 to CHO cells expressing WT
Table II. Conformational Sensitivity of the Amino Acids 
Involved in iC3b Binding
Ca-metal distance ()* Ca-metal distance ()
aa (Open/Closed) D () aa (Open/Closed) D ()
T203 15.42/15.35 0.07 G143 5.70/6.20 0.50
Q204 11.66/11.70 0.04 D149 11.70/11.30 0.40
F246 6.50/9.00 2.50 E178 9.50/10.80 1.30
E244 5.50/7.30 1.80 E179 12.10/13.20 1.10
D273 11.30/10.10 1.20 R208 5.60/6.60 1.00
E278 16.00/18.30 2.30
K279 13.30/16.80 3.50
*Distances in angstroms are measured from the a carbon atom of each residue in the
open and closed conformation to the respective metal ion. The residues that only af-
fect iC3b binding are shown at the left, whereas those that also affect NIF binding are
shown at the right.
Figure 4. Effects of muta-
tions involving F302, F275,
and T209 on iC3b, fibrinogen,
and NIF binding to recombi-
nant membrane-bound CR3.
(A) Histograms (mean 6
SEM, n 5 3) showing the
normal cell surface expres-
sion of the mutant CR3 on
transfected COS cells, as
checked by anti-CD11b mAb
903 and anti-CD18 mAb TS1/
18. (B) Histograms (mean 6
SEM, n 5 4) showing the
binding of mutant CR3 expressed on COS cells to iC3b and NIF. (C) Histograms (mean 6 SEM, n 5 3) showing the binding of WT or
F302W CR3-transfected CHO cells to iC3b and fibrinogen (Fg). The surface expression levels of both WT and F302W receptors were
z70% (data not shown).The Journal of Cell Biology, Volume 143, 1998 1530
or F302W CR3. In six independent experiments (one of
which is shown in Fig. 5), we found that the fraction of
CR3 recognized by 7E3 was 5.95 6 1.6% of total CR3 for
WT and 14.9 6 3.47% for F302W. Thus the F302W substi-
tution increases the fraction of high affinity CR3 in whole
cells. Increased binding of iC3b and 7E3 to F302W r11bA
was also observed (Fig. 6), whereas binding of NIF was un-
changed. Taken together, the above findings indicate that
a conformational change intrinsic to the A-domain en-
hances the binding of the holoreceptor as well as the iso-
lated A-domain to activation-dependent ligands. Since
7E3 is a marker of the high affinity state, the observed in-
crease in receptor binding appears to largely result from a
change in receptor affinity.
Binding Properties of the T209A Receptor
The third major distinguishing feature between the two
r11bA conformations is the shift in metal coordination
from a direct coordination of T209 with the metal in the
open form to a break in T209Ðmetal bond in the closed
form (Fig. 1). We assessed the functional significance of
this shift on metal binding and receptor activation. We
first reasoned that if the two Mn21-containing structures
have biologic relevance, then a T209A mutation should
not compromise the ability of r11bA to bind the metal ion.
This was in fact the case: the normally expressed (Fig. 4 A)
and heterodimeric (Kamata et al., 1995b; and data not
shown) T209A CR3 bound normally to the activation-
independent ligand NIF (Fig. 4 B). Since NIF binding re-
quires divalent cations and an intact MIDAS (the metal-
defective CR3 mutants D140GS/AGA or D242A do not
bind to NIF [Rieu et al., 1994]), this finding indicates that
the T209A CR3 can coordinate the metal ion in the MI-
DAS site. We then assessed the effect of T209A on recep-
tor activation as quantified by binding to iC3b. As shown
in Fig. 4 B, T209A receptor did not bind to iC3b in the
presence of divalent cations. Similar results were obtained
when binding of NIF and iC3b to the isolated T209A
A-domain was carried out (Fig. 6). Interestingly, introduc-
ing the F302W mutation in T209A failed to restore any
binding of the double mutant to iC3b (Fig. 4 B). A previ-
ous study (Kamata et al., 1995b) showed that a T209A mu-
tation in the holoreceptor abolished its ability to bind to
another activation-dependent ligand CD54, but suggested
that this was caused by loss of metal coordination. The
present findings clearly show an intact metal coordination
site in the T209A mutant as judged by the normal binding
of NIF. Therefore, these data suggest that direct coordina-
tion of the metal ion by T209 (as in the open conforma-
tion) is a necessary feature of the activated state. Switch-
ing this coordination from T209 to D242 as in the closed
Figure 5. Interaction of mAb 7E3 with WT or F302W-trans-
fected CHO cells. Expression of the activation-specific 7E3 epi-
tope on WT, F302W, or Neo-transfected CHO cells was exam-
ined by flow cytometry. mAb 44, which recognizes the whole
population of CR3, was used as a reference. Mouse IgG1 (dotted
lines) was used to determine background fluorescence. The frac-
tion of CR3 recognized by 7E3 is 5.95 6 1.16% for WT and 14.9 6
3.47% for F302W (n 5 6).
Figure 6. Effects of F302W
and T209A on direct binding
of purified r11bA to iC3b,
NIF, and mAb 7E3. (A) His-
tograms (mean 6 SEM, n 5
3) showing that equivalent
amounts of WT and mutant
r11bA were immobilized
onto 96-well plates. (B) His-
tograms (mean 6 SEM, n 5
5) showing a selective gain of
binding of F302W to iC3b but
not to NIF, and a selective loss
of binding of T209A to iC3b
but not to NIF. (C) Histo-
grams (mean 6 SEM, n 5 4)
showing a gain of F302W
binding to mAb 7E3 and a loss
of T209A binding to this mAb.Li et al. Affinity Modulation in Integrins 1531
conformer generates an inactive receptor. Taken together,
the above data show that all three features of the open
conformation (the change in the topology of the MIDAS
face, the solvent accessibility of side chains at positions 302
and 275, and the direct coordination of the metal by T209)
are relevant to enhancing CR3 or r11bA binding to activa-
tion-dependent ligands, suggesting a functional signifi-
cance for these linked structural features.
Figure 7. Sensorgrams recording interactions of WT or F302W A-domains with immobilized iC3b and mAb 904. Overlay plot of sensor-
grams recorded the injection of 1 mM of WT (solid lines) or F302W (dashed lines) A-domains at a flow rate of 5 ml/min for 6 min through
the iC3b- (A) or mAb 904Ðcoated (B) chips. Arrows indicate the beginning and end of injection.
Figure 8. Equilibrium analysis of the interaction of WT or F302W A-domains with immobilized iC3b. Concentrations ranging from 0.5
to15 mM for WT (A) and 0.5 to 12 mM for F302W (B) were injected at a flow rate of 5 ml/min for 6 min to reach equilibrium. C (for WT)
and D (for F302W) show the respective saturable binding curves and Scatchard plots (insets).The Journal of Cell Biology, Volume 143, 1998 1532
Two Functional States for the A-Domain
Exist in Solution: Effect of the F302W Mutation on
the Active State
A simple model that explains the above functional and
structural studies is that the isolated r11bA exists in two
functional states in solution, one active (defined by its abil-
ity to bind to activation-dependent ligands) and the other
inactive (although still able to bind certain antagonists
such as NIF). Activating mutations (such as F302W) or in-
activating mutations (such as T209A) change the relative
abundance of these two states. To test this model, we used
surface plasmon resonance (Malmqvist, 1993) and exam-
ined the binding of WT and F302W r11bA to iC3b and
mAb 904, an activation-independent and metal-indepen-
dent ligand. When 1 mM of WT and F302W was injected
onto the BIAcoreª sensor chip coupled to excess iC3b, an
approximately twofold increase in binding of F302W was
observed compared with WT (Fig. 7 A), in agreement with
the other binding data presented in Figs. 4Ð6. When the
same amounts of WT and F302W were injected onto the
mAb 904Ðcoupled chip surface, no difference in the bind-
ing level was found (Fig. 7 B). This indicates that equiva-
lent amounts of WT and F302W r11bA were available for
binding. Injection of increasing concentrations of the WT
r11bA ranging from 0.5 to 15 mM at a flow rate of 5 ml/min
gave a saturable binding curve (Fig. 8, A and C). Scatchard
plot of the binding data was linear, with a dissociation con-
stant  Kd of 3.8 mM (Fig. 8 C). A similar analysis using
F302W revealed an almost identical affinity (Fig. 8, B and
D). The observed ligand-binding affinity was significantly
lower than that reported for binding of purified CR3 to
ligands (Kd z12.5Ð200 nM) (Berman et al., 1993; Cai and
Wright, 1995). One interpretation for this difference is
that the A-domain preparation contains only a subpopula-
tion of active species. Biosensor technology can be used to
measure the active analyte in a protein preparation under
conditions where binding to ligand (present in excess) is
only limited by the diffusion of the analyte to the surface-
bound ligand. Under these conditions, initial binding rates
are proportional to the active analyte concentration and
independent of the analyte-ligand affinity. This can be val-
idated experimentally by demonstrating that the initial
binding rate is independent of ligand density (Karlsson
et al., 1993). We used mAb 904 in parallel in order to esti-
mate total binding. By decreasing the flow rate and in-
creasing the ligand density, the binding rate of WT and
F302W r11bA to chips coated with iC3b or mAb 904 can
be made independent of the respective ligand density (Ta-
ble III) and therefore a function of the concentration of
the binding active species. In WT, this active species repre-
sented z11 6 1.7% of the total r11bA (Table IV). In par-
allel experiments, we showed that the proportion of the
active species in F302W increased by z2.5-fold (25 6
1.1%). The fact that a major portion of F302W remains in
the inactive state probably reflects other structural consid-
erations that allow motion of the a7 helix to that of the
closed form, despite a partial burial of the side chain at po-
sition 302. The recent structure of the CD49b A-domain
shows that this does in fact occur: the orientation of the a7
helix is very similar to that in the closed form of r11bA,
despite only a partial burial of the side chain of E318
(equivalent to F302) at the top of the a7 helix (Emsley et
al., 1997). Since, the total amount of r11bA was used in
calculating the binding affinities shown in Fig. 8, the affin-
ity of the active species should be z10-fold higher, ap-
proaching that calculated for purified CR3 and of the ac-
tive cell-bound form of CD11a/CD18 (Lollo et al., 1993).
In summary, the r11bA exists in two functional states in
solution as assessed by BIAcoreª. These two forms are
equally capable of interacting with activation-independent
ligands such as NIF, but display marked differences in
their affinity to physiologic ligands such as iC3b, fibrino-
gen, and the ligand mimetic mAb 7E3. The two states ap-
pear to be in a dynamic equilibrium with a majority of the
domain in an inactive state (defined as one incapable of
binding to activation-dependent ligands, due to the lack of
an activation-specific ligand-binding interface). This equi-
librium can be modulated both positively or negatively by
certain mutations (described in this report) and perhaps
by others (Zhang and Plow, 1996a). Based on the func-
tional analysis of the various A-domain mutants, we also
suggest that the active and inactive states may correspond
to the open and closed structures, respectively. In this
scenario, analogous movement of the COOH-terminal a7
helix of the A-domain in the holoreceptor switches the re-
ceptor to its active state. Since a MIDAS-like ligand-bind-
ing motif is present in all b subunits, an affinity switch not
unlike that of G proteins may be operational on the extra-
cellular face in all integrins.
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Table III. Initial Binding Rates of WT and F302W on iC3b and 
mAb 904 Surfaces with Two Different Ligand Densities
Initial binding rates (RU/S)
iC3b* mAb 904
nM 6,300 RU 8,000 RU 4,200 RU 6,200 RU
WT 200 1.96 1.93 16.5 18.3
500 5.32 5.83 41.7 39.9
F302W 200 4.14 4.38 15.9 17.1
500 11.8 12.2 40.1 43.1
*No significant differences in binding rates were observed from two different sur-
faces of iC3b and 904, indicating the rates were independent of ligand density, there-
fore they were mass transfer limiting binding rates.
Table IV. Initial Binding Rates of WT and F302W on iC3b and 
mAb 904 Surfaces with High Ligand Densities (.8,000 RU for 
iC3b, .6,000 RU for mAb 904), and Relative Percentages of 
Active Proportions of A-Domain Proteins
Initial binding rates (RU/S)
iC3b mAb 904 % active
nM WT F302W WT F302W WT F302W
37.5 0.68 1.33 5.84 5.64 11.6 23.6
75 1.48 2.81 12.0 11.2 12.3 25.1
150 2.15 5.71 23.7 22.1 9.1 25.8
Data shown are from one representative experiment out of three performed.Li et al. Affinity Modulation in Integrins 1533
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